“It’s building the plane and flying the plane at the same time.”
That was how Sandoz CEO Richard Saynor described the experience of running the world’s largest generics and biosimilars firm,...
A Year Of Change: Sandoz Completes A Transformational 2023
Spinoff From Novartis Caps A Year That Also Saw Plenty Of Deals And Launches
Listen to this article
An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.
Stay ahead of every shift in generics and biosimilars.
More from Strategy
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
More from Business
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains